- Home
- MFA vs MLTX Comparison
MFA vs MLTX Comparison
Compare MFA & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MFA | MLTX |
|---|---|---|
| Founded | 1997 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MFA | MLTX |
|---|---|---|
| Price | $10.06 | $18.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $11.05 | ★ $25.70 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | ★ 14.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.39 | $5.95 |
| 52 Week High | $11.08 | $62.75 |
Technical Indicators
Market Signals| Indicator | MFA | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 62.33 |
| Support Level | $8.94 | $17.00 |
| Resistance Level | $10.28 | $19.15 |
| Average True Range (ATR) | 0.24 | 0.96 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 61.86 | 57.43 |
Price Performance
Historical ComparisonAbout MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.